HC Deb 02 March 1994 vol 238 cc760-1W
Mrs. Golding

To ask the Secretary of State for Health what plans her Department has to allow the introduction of the drug AZT to(a) mothers-to-be and (b) other patients suffering from HIV and AIDS.

Mr. Sackville

Zidovudine, AZT, is currently licensed in the United Kingdom for the following indications.

he management of patients with advanced HIV disease, such as those with the acquired immune deficiency syndrome (AIDS) or AIDS-related complex (ARC).

in adult patients with HIV infection.

in early symptomatic patients with CD4 counts of less than 500/mm3, or in asymptomatic patients with markers indicating risk of progressive disease including repeated CD4 counts of less than 200/mm3, or with CD4 counts between 500/mm3 and 200/mm3 which are rapidly falling.

HIV-infected children over the age of 3 months who have HIV-related symptoms or who are asymptomatic with markers indicating significant HIV-related immune suppression.

Applications for the licensing of any further indications will be considered by the Medicines Control Agency according to established procedures.